This disease can cause
cirrhosis of the liver as well as liver cancer. However, this virus is
sexually transmitted. People at high risk for getting hepatitis B disease
(which is transmitted by coming into direct contact with an infected
person's body fluids) are IV drug users, prostitutes, prisoners, and
sexually promiscuous persons. This
vaccine is produced from cultures commonly found in baker’s yeast. The vaccine is
treated with formaldehyde and contains 95 percent hepatitis B virus surface
antigen, 4 percent yeast protein, and aluminum hydroxide. The only babies at risk
for this disease are babies born to
Hepatitis B positive mothers and it is
just that, a risk, not a given. In 1996, fifty-four cases were reported to
the Center for Disease Control in the birth-to-1 age group. There were 3.9
million babies born that year so the incidence of hepatitis B is 0.001%.
Does that sound like enough cases to warrant a vaccine? 90 to 95% of all
hepatitis B cases recover completely after 3 to 4 weeks of nausea, fatigue,
headache, arthritis, jaundice and tender liver. Approximately 50% of
patients who contract Hepatitis B develop no symptoms after exposure.
However, the exposure ensures that they will have life-time immunity. An
additional 30% develop only flu-like symptoms, and again, this group will
acquire life-time immunity. Of the remaining 20% exposed to Hepatitis B will
develop the symptoms of the disease. 95% of this 20% will fully recover,
with life-time immunity. Therefore, less than 5% of people who contract
Hepatitis B will become chronic carriers of the infection.
Up to 17 percent of all
hepatitis B vaccinations are followed by reports of fatigue and weakness,
headache, arthritis and fever of more than 100 F. The vaccine can cause
death, according to a
1994 Institute of Medicine report.
Hepatitis B vaccine is the first one a baby is subjected to at
old. This is in hopes it will protect them when they are older. Developed in
1987, little is known whether immunity will last until one might fall into a
high-risk category. It was originally targeted for promiscuous, needle
injecting drug users, but when they wouldn’t come in for the shots the CDC
decided to get these kids before they started “using.”
Paradoxically, the CDC's own Fact Sheet on the hepatitis B disease does
not include newborn babies as a risk group for that disease. So in the
CDC’s own words, almost every newborn US baby is now greeted on its entry
into the world by a vaccine injection against a sexually transmitted
disease for which the baby is not at risk. All this because they couldn't
get the junkies, prostitutes, promiscuous heterosexuals and homosexuals
they believe to be at risk, to take the vaccine. This is the essence of
the hepatitis B
universal vaccination program.
Physician's Desk Reference cites lethal adverse reactions to the hepatitis B
in less than 1 percent. However, if more than 70 million American children
receive the vaccine that means more than 700,000 children are likely to die.
An ongoing holocaust, to which we hear nothing about. This is just one of
twenty different doses of vaccines. Once you assume that
a certain number of children are expendable, where do you draw the line?
The central fact, and the
one that helps to explain these insane recommendations, is that the maker of
hepatitis B vaccine, Merck makes one billion
dollars a year from this vaccine. A billion dollars a year goes a long way
toward influencing public policy.
The group that is pushing
this through is called The Hepatitis B coalition. Part of the Immunization
Action Coalition, this group was started by a $750,000 grant from the CDC.
The World Health Organization, World Bank, Rockefeller Foundation and
ongoing funding from Smith-Kline, Merck, Aventis and Johnson & Johnson
In the single dose hepatitis
B vials, the drug companies have replaced the mercury with aluminum, which
is another potent neurotoxin that has been associated with
Alzheimer's. But who knows
what damage it will do to the immature central nervous system of a one-day
manufacturer's representative was asked in a 1997 Illinois Board of Health
hearing to show evidence that the hepatitis B vaccine is safe for a 1-day
old infant. The representative stated:
were done on 5- and 10-year-olds."
Quarterly, August 25, 2000, pg. 647
Merck’s package insert
states the following adverse effects have been documented; Rheumatoid
Arthritis, Influenza, Vertigo, Myalgia, earache, dysuria, hypotension,
myelitis, peripheral neuropathy such as Bell’s Palsy, radiculopathy and
visual disturbances. Nothing is known about the long-term effects of this
vaccine as no long-term large-scale controlled studies have been done.
Children under the age of fourteen are three times more likely to suffer
adverse effects including death following the Hepatitis B vaccine than to
catch the disease itself.
For more adverse effects
The only recombinant vaccine
currently in use in humans is the Hepatitis B Virus (HBV)
are those in which genes for desired antigens are inserted into a vector,
usually a virus, that has a very low virulence.
The vector expressing the antigen may be used as the vaccine, or the antigen
may be purified and injected as a subunit vaccine. Advantages of recombinant
vaccines are that the vector can be chosen to be not only safe but also easy
to grow and store, reducing production cost. Antigens which do not elicit
protective immunity or which elicit damaging responses can be eliminated
from the vaccine, and proteins expressed on a virus, even if it is not the
usual pathogen, are more likely to have their native conformation.
Disadvantages of recombinant vaccines are their cost to develop, since the
genes for the desired antigens must be located, cloned, and expressed
efficiently in the new vector. The only recombinant vaccine currently in use
in humans is the Hepatitis B Virus (HBV) vaccine, which is a recombinant
subunit vaccine. Hepatitis B surface antigen is produced from a gene
transfected into yeast cells and purified for injection as a subunit
vaccine. This is much safer than using attenuated HBV, which could cause
lethal hepatitis or liver cancer if it reverted to its virulent phenotype.
1997, U.S. federal health officials acknowledged that one of their own
studies showed that particularly in older children, the vaccine may increase
insulin dependent diabetes mellitus, but more studies are needed.
France has already discontinued the Hepatitis B vaccine.
Here is one study from there.
Autoimmun Rev. 2005 Feb;4(2):96-100. Related Articles, Links
Autoimmune hazards of hepatitis B vaccine.
1 bd de la Republique 78000-Versailles, France.
According to Hippocratic tradition, the safety level of a preventive
medicine must be very high, as it is aimed at protecting people against
diseases that they may not contract. This paper points out that
information on the safety of hepatitis B vaccine (HBV) is biased as
compared to classical requirements of evidence-based medicine (EBM), as
exemplified by a documented selectivity in the presentation or even
publication of available clinical or epidemiological data. Then, a review
is made of data suggesting that HBV is remarkable by the frequency, the
severity and the variety of its complications, some of them probably
related to a mechanism of molecular mimicry leading to demyelinating
diseases, and the others reproducing the spectrum of non-hepatic
manifestations of natural hepatitis B. To be explained, this unusual
spectrum of toxicity requires additional investigations based upon
complete release of available data.
PMID: 15722255 [PubMed - as supplied by publisher]
If you would like to see the package insert on how this vaccine is made click on the healthy
Here is an excerpt:
The antigen is harvested and purified from
fermentation cultures of a recombinant strain of the yeast
Saccharomyces cerevisiae containing the gene for the adw subtype of
HBsAg. The fermentation process involves growth of Saccharomyces
cerevisiae on a complex fermentation medium which consists of an extract
of yeast, soy peptone, dextrose, amino acids and mineral salts. The HBsAg
protein is released from the yeast cells by cell disruption and purified
by a series of physical and chemical methods. The purified protein is
treated in phosphate buffer with formaldehyde and then coprecipitated
with alum (potassium aluminum sulfate) to form bulk vaccine adjuvanted
with amorphous aluminum hydroxyphosphate sulfate. The vaccine contains no
detectable yeast DNA but may contain not more than 1% yeast protein. The
vaccine produced by the Merck method has been shown to be comparable to
the plasma-derived vaccine in terms of animal potency (mouse, monkey, and
chimpanzee) and protective efficacy (chimpanzee and human).
Look at the words in bold and read these studies.
Alimentary Pharmacology & Therapeutics
Volume 21 Issue 7 Page 881 - April 2005
Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil cytoplasmic
antibodies in coeliac disease before and after gluten-free diet
A. Granito*, D. Zauli*, P. Muratori*, L. Muratori*, A. Grassi*, R.
Bortolotti*, N. Petrolini*, L. Veronesi*, P. Gionchetti, F. B. Bianchi* &
Background: Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil
cytoplasmic autoantibodies are markers of Crohn's disease and ulcerative
Aim: To determine the prevalence of anti-S. cerevisiae and perinuclear
anti-neutrophil cytoplasmic autoantibodies in a large series of coeliac
disease patients before and after gluten free diet, and to correlate
anti-S. cerevisiae-positivity with intestinal mucosal damage.
Methods: One hundred and five consecutive coeliac disease patients and
141 controls (22 ulcerative colitis, 24 Crohn's disease, 30 primary
sclerosing cholangitis, 15 postenteritis syndrome, 50 blood donors) were
tested for anti-S. cerevisiae by enzyme-linked immunosorbent assay and
for perinuclear anti-neutrophil cytoplasmic autoantibodies by indirect
Results: In coeliac disease anti-S. cerevisiae (immunoglobulin G and/or
immunoglobulin A) were slightly less frequent (59%) than in Crohn's
disease (75%, P = 0.16) and significantly more frequent than in
ulcerative colitis (27%), primary sclerosing cholangitis (30%),
postenteritis syndrome (26%) and blood donors (4%) (P = 0.009, P =
0.0002, P = 0.025, P < 0.0001). No correlation was found between anti-S.
cerevisiae and degree of mucosal damage. Perinuclear anti-neutrophil
cytoplasmic autoantibodies were detected only in one coeliac. After
gluten free diet the disappearance of anti-S. cerevisiae-immunoglobulin A
(93%) was more frequent than that of immunoglobulin G (17%, P = 0.0001);
perinuclear anti-neutrophil cytoplasmic autoantibodies disappeared in the
only coeliac positive at diagnosis.
Conclusion: More than half of untreated coeliacs are anti-S. cerevisiae-positive
irrespective of the severity of mucosal damage. Differently from
immunoglobulin A, anti-S. cerevisiae-immunoglobulin G persisted in more
than 80% after gluten free diet. The high prevalence of anti-S.
cerevisiae in coeliac disease suggests that they may be the effect of a
non-specific immune response in course of chronic small bowel disease.
I wonder if there is some connection?
Here is another study.
|Clinical & Experimental
Volume 140 Issue 2 Page 354 - May 2005
|CARD15 polymorphisms are
associated with anti-Saccharomyces cerevisiae antibodies in
caucasian Crohn's disease patients
|B. Vander Cruyssen*,1,
I. E. A. Hoffman*,
E. M. Veys*,
M. De Vos
and F. De Keyser*
Carriage of CARD15 gene polymorphisms and
the serological marker anti-Saccharomyces cerevisiae
antibodies (ASCA) are two markers for Crohn's disease (CD).
Similar phenotypes have been associated with both markers. In the
present study we analysed whether both markers were associated with
each other and, if so, whether this association could be explained by
a direct link or by an indirect association with those phenotypes.
Therefore, we included 156 consecutive Caucasian CD patients and
assessed the prevalence of the three common single nucleotide
polymorphisms in the CARD15 gene. Serum samples were analysed
for IgA and IgG ASCA by ELISA. CD patients with CARD15
polymorphisms were more frequently ASCA positive (OR 2·7 (1.45.2);
P = 0·002) and had higher titres for ASCA IgA (P = 0·005)
and ASCA IgG (P < 0·001) compared to patients carrying the
wild type polymorphisms. Multivariate analysis demonstrated that this
association was independent from ileal disease, penetrating disease
and stricturing disease, the need for resective bowel surgery,
familial cases, smoking habits and early age at onset. Homozygotes or
compound heterozygotes for CARD15 polymorphisms had
significantly more frequent ASCA positivity compared to single
heterozygotes (OR 9·1 (1.174.2),
Pc (corrected P-value) = 0·030). These data
indicate that there is a significant association between the carriage
of CARD15 polymorphisms and ASCA, independent of the described
phenotypes. Moreover, ASCA positivity is more frequent in CD patients
carrying 2 CARD15 polymorphisms compared to single
Gluten for punishment: Better eating puts celiac symptoms on the shelf
By Heather V. Eng
Sunday, August 7, 2005
Do you know the Muffin Man?
Unless he's bearing gluten-free baked goods, more than 2 million Americans
living with celiac disease avoid him like the plague. The autoimmune disease
causes inflammation in the small intestine when gluten proteins from wheat,
rye, barley and related grains are ingested. Celiac disease once was thought
rare, but now is believed to affect 1 in 133 Americans. ``I'm seeing a lot
more kids with celiac disease, but it's because of increased awareness of
patients and pediatricians,'' said Dr. Gary Russell, a pediatric
gastroenterologist at Massachusetts General Hospital.
Increased awareness? Or more kids getting Hep B vaccine at birth? If this isn't enough to help you make a decision not to inject your baby
with Hep B vaccine, let me tell you about a company making a new Hep B
vaccine for use first in England. Why England is not learning from the
first lesson is beyond me.
The company is named Corixa and the new
vaccine is called Fendrix. Here is the web
In case it disappears, I have saved it here
SEATTLE, February 8, 2005
Corixa Corporation (Nasdaq: CRXA), a
developer of immunotherapeutics, today announced that GlaxoSmithKline
Biologicals (GSK Bio) has received European approval for its hepatitis B
vaccine, Fendrix®, containing Corixa’s MPL®
of the first vaccines made with an extremely dangerous oil based adjuvant
was 'Vaccine A' or Anthrax vaccine. In his book lauded Author Gary
Matsumoto has ruthlessly documented the account of the
cover-up of the true cause of Gulf War syndrome. He began his research while an embedded reporter for the New York Times
during the first Gulf War. In his book Gary Matsumoto chronicles the use of this
adjuvant from its early beginnings as Freund's complex through all of its incarnations.
Other names for the adjuvant have been squalene, Tri-mix, DeTox,
MF-59, MF59-100 and now the latest MPL. Experiments started in the 30’s, and
by the 50’s scientists knew this adjuvant caused autoimmune diseases. Some
of the side effects of the earlier versions are allergic spermatogenesis
(stoppage of sperm production), MS, neuritis, blindness, lupus.
The problem is the adjuvant is an oil closely resembling the body's own
lipids. It is designed to stimulant a heightened immune response which it
does with a vengeance. Unfortunately after a period of time the body
can become confused and attack it's own very similar oil or lipids.
This process is called autoimmune. Russian researchers have referred to this
adjuvant as a 'time bomb.' This book chronicles the experiments done on our
service men and the carnage that has resulted. The latest of the experiments
is about to begin on Europe's smallest, twelve hour old babies in England.
Since this vaccine is given so soon after birth, the resulting problems may
not initially be attributed to the vaccine. We will have to watch England's
babies closely to see if we lose another generation of kids to autoimmune
diseases and sterility. Take a look at what doctors at the University of Florida
about the adjuvant here:
Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine.
Division of Rheumatology and Clinical Immunology,
Department of Medicine, University of Florida, ARB-R2-156, 1600 SW Archer
Road, P.O. Box 100221 Gainesville, FL 32610-0221, USA.
Adjuvant oils such as Bayol F (Incomplete Freund's
adjuvant: IFA) and squalene (MF59) have been used in human and veterinary
vaccines despite poor understanding of their mechanisms of action. Several
reports suggest an association of vaccination and various autoimmune
diseases, however, few were confirmed epidemiologically and the risk of
vaccination for autoimmune diseases has been considered minimal. Microbial
components, not the adjuvant components, are considered to be of primary
importance for adverse effects of vaccines. We have reported that a single
intraperitoneal injection of the adjuvant oils pristane, IFA or squalene
induces lupus-related autoantibodies to nRNP/Sm and -Su in non-autoimmune
BALB/c mice. Induction of these autoantibodies appeared to be associated
with the hydrocarbon's ability to induce IL-12, IL-6, and TNF-alpha,
suggesting a relationship with hydrocarbon's adjuvanticity. Whether this is
relevant in human vaccination is a difficult issue due to the complex
effects of vaccines and the fact that immunotoxicological effects vary
depending on species, route, dose, and duration of administration.
Nevertheless, the potential of adjuvant hydrocarbon oils to induce
autoimmunity has implications in the use of oil adjuvants in human and
veterinary vaccines as well as basic research. Copyright 2004 Elsevier SAS
PMID: 15194169 [PubMed - indexed for MEDLINE
How much money is made on this vaccine? Here is except from this article
SciGen aims for a share of the
multibillion hep B vaccine market
By Susan Gotensparre
22/01/2007- Biopharmaceutical firm SciGen has invested $30m (€23.2m) in a
hepatitis B vaccine manufacturing plant in Israel, expecting to capture up
to 15 per cent of the global market during a three year period.
SciGen has announced the official opening of its $20m (€15.5m) vaccine
manufacturing facility in Israel, supplying three million doses of the
company’s third generation hepatitis B vaccine, Sci-B-Vac. The company is
boosting their vaccine manufacturing to be able to ensure supply to their
European and Asian commercial partners. In addition, a further $10m (€7.7m)
has been invested to expand the Israeli facilities.
The world market for hepatitis B is $1.2bn
(€0.93bn) - Europe and the Asia Pacific region represent 40 per cent - but
is expected to increase due to rising awareness of hepatitis B and increased
public health expenditure, according to SciGen. The firm has high
expectations of explosive annual sales figures from the third quarter of
2007, followed by an anticipated triple digit growth in 2008.
Take a look at this:
VACCINES are listed as a cause more than once:
Background: Gianotti-Crosti syndrome (GCS) is a distinct infectious
exanthem with associated lymphadenopathy and acute anicteric hepatitis.
Gianotti and Crosti initially described GCS as associated with a hepatitis
B virus exanthem, which they termed papular acrodermatitis of childhood. A
similar constellation of
characteristics was later found to be associated with several infectious
agents and immunizations that were called papulovesicular acrolocated
syndromes. Subsequent retrospective studies have shown that these 2
entities are indistinguishable from one another, and they are now
consolidated under the unifying title of GCS.
Pathophysiology: The most likely explanation for the exanthem is a local
type IV hypersensitivity reaction to the offending viral or bacterial
antigen within the dermis. This is based on the immunohistochemical
characterization of the cutaneous inflammatory infiltrate. Findings on
direct immunofluorescence examination of the skin are always negative.
Electron microscopy has never revealed virus particles that suggested a
reactive process other than an autoimmune phenomenon or direct infection
of the skin. Inciting factors include various viral and bacterial
infections, as well as recent immunizations. The rarity of GCS in adults
suggests lifelong immunity to a common viral triggering agent. GCS is more
common among children with atopic dermatitis, suggesting an immune
mechanism. However, more information is needed in order to define the
precise mechanism involved.
* In the US: Because of the benign self-limited nature of GCS, most cases
are not reported, and the overall incidence is unknown. Frequency probably
parallels the incidence of a precipitating infection in a specific
* Internationally: The underlying infection correlates with the endemic
pathogens of a specific geographic region. For example, in Japan and
Mediterranean countries, GCS is more commonly associated with hepatitis B
virus infection. With the advent of more universal hepatitis B
immunization, Epstein-Barr virus is now the most common etiologic factor
* The mere presence of a rash elicits some degree of social morbidity,
depending on the age of the affected child.
* Although typically nonpruritic, some reports document pruritus in the
later stages of the rash.
* The only significant morbidity involves the underlying infectious
process, particularly the hepatitis B virus.
Race: No racial predilection has been noted; however, the underlying
infection correlates with the endemic pathogens of a specific geographic
Sex: In the pediatric population, GCS affects males and females with equal
frequency. However, affected adults have been exclusively female.
Age: GCS primarily occurs in children aged 3 months to 15 years, with a
peak in children aged 1-6 years. More than 90% of patients are younger
than 4 years.